C-Reactive Protein Level Is an Indicator of the Aggressiveness of Advanced Pancreatic Cancer

Pancreas

Volumn 45, Issue 1, 2016, Pages 110-116

  Mitsunaga, Shuichi ^a   Ikeda, Masafumi ^a   Shimizu, Satoshi ^a   Ohno, Izumi ^a   Takahashi, Hideaki ^a   Okuyama, Hiroyuki ^a   Ueno, Hideki ^b   Morizane, Chigusa ^b   Kondo, Shunsuke ^b   Sakamoto, Yasunari ^b   Okusaka, Takuji ^b   Ochiai, Atsushi ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

C reactive protein; cachexia; chemotherapy; gemcitabine; pancreatic cancer; prognostic factor

Indexed keywords

C REACTIVE PROTEIN; GEMCITABINE; INTERLEUKIN 6; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; TUMOR MARKER;

ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SIZE; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; ANALOGS AND DERIVATIVES; BLOOD; CLASSIFICATION; HEALTH STATUS; KAPLAN MEIER METHOD; KARNOFSKY PERFORMANCE STATUS; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PANCREATIC NEOPLASMS; PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; REPRODUCIBILITY; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; TUMOR VOLUME; VALIDATION STUDY;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BIOMARKERS, TUMOR; C-REACTIVE PROTEIN; DEOXYCYTIDINE; FEMALE; HEALTH STATUS; HUMANS; KAPLAN-MEIER ESTIMATE; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84952714638     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0000000000000465     Document Type: Article

References (24)

1. Fearon K, Barbar M, Falconer J, Pancreatic cancer as a model: inflammatory mediators, acute-phase response, and cancer cachexia. World J Surg. 1999; 23: 584-588.
2. Roxburgh C, McMillan D,. Cancer and systemic inflammation: treat the tumour and treat the host. Br J Cancer. 2014; 110: 1409-1412.
3. Hanahan D, Weinberg RA,. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646-674.
4. Yu H, Pardoll D, Jove R,. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009; 9: 798-809.
5. Proctor M, Morrison D, Talwar D, A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer. 2011; 47: 2633-2641.
6. Stotz M, Gerger A, Eisner F, Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer. 2013; 109: 416-421.
7. Szkandera J, Stots M, Absenger G, Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients. Br J Cancer. 2014; 110: 183-188.
8. Morrone G, Ciliberto G, Oliviero S, Recombinant interleukin 6 regulates the transcriptional activation of a set of human acute phase genes. J Biol Chem. 1988; 263: 12554-12558.
9. Young DP, Kushner I, Samols D,. Binding of C/EBPbeta to the C-reactive protein (CRP) promoter in Hep3B cells is associated with transcription of CRP mRNA. J Immunol. 2008; 181: 2420-2427.
10. Argilés JM, López-Soriano FJ, Toledo M, The cachexia score (CASCO): a new tool for staging cachectic cancer patients. J Cachexia Sarcopenia Muscle. 2011; 2: 87-93.
11. Pine JK, Fusai KG, Young R, Serum C-reactive protein concentration and the prognosis of ductal adenocarcinoma of the head of pancreas. Eur J Surg Oncol. 2009; 35: 605-610.
12. Falconer JS, Fearon KC, Ross JA, Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer. 1995; 75: 2077-2082.
13. Nakachi K, Furuse J, Ishii H, Prognostic factors in patients with gemcitabine-refractory pancreatic cancer. Jpn J Clin Oncol. 2007; 37: 114-120.
14. Sobin LH, Gospodarowicz MK, Wittekind C,. TNM Classification of Malignant Tumors. 7th ed. Oxford: Wiley-Blackwell; 2009.
15. Mitsunaga S, Ikeda M, Shimizu S, Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer. 2013; 108: 2063-2069.
16. Von Hoff DD, Ervin T, Arena FP, Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369: 1691-1703.
17. Eisenhauer EA, Therasse P, Bogaerts J, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45: 228-247.
18. Kernan WN, Viscoli CM, Makuch RW, Stratified randomization for clinical trials. J Clin Epidemiol. 1999; 52: 19-26.
19. Ueno H, Ioka T, Ikeda M, Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 2013; 31: 1640-1648.
20. Fearon K, Strasser F, Anker SD, Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011; 12: 489-495.
21. Fujii S, Mitsunaga S, Yamazaki M, Autophagy is activated in pancreatic cancer cells and correlates with poor patient outcome. Cancer Sci. 2008; 99: 1813-1819.
22. Heinecke JL, Ridnour LA, Cheng RY, Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression. Proc Natl Acad Sci U S A. 2014; 111: 6323-6328.
23. Hurwitz H, Uppal N, Wagner AS, A randomized double-blind phase 2 study of ruxolitinib (RUX) or placebo (PBO) with capecitabine (CAPE) as second-line therapy in patients (pts) with metastatic pancreatic cancer (mPC) [Abstract 4000]. J Clin Oncol. 2014; 32 (suppl): 5s.
24. Conroy T, Desseigne F, Ychou M, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364: 1817-1825.